P. Mann

发表

Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study

C. Lanata, A. Gil, G. Leroux-Roels, 2022, Vaccine: X.

Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen

S. McCormack, M. Hoelscher, M. Robb, 2012, Retrovirology.

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2

N. Klopp, P. Kremsner, M. Fotin‐Mleczek, 2021, Wiener klinische Wochenschrift.

High prevalence of ST-elevation, early repolarization, and left ventricular hypertrophy during the eligibility assessment for an HIV vaccine trial in young, healthy Tanzanians

S. McCormack, M. Hoelscher, M. Robb, 2017 .

A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant

L. Oostvogels, Sarah-Katharina Kays, G. Quintini, 2022, Vaccines.

Third dose of COVID-19 vaccine, CVnCoV, increased neutralizing activity against SARS-CoV-2 wild-type and Delta variant

L. Oostvogels, Sarah-Katharina Kays, G. Quintini, 2022, medRxiv.

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

Allan C. deCamp, J. Kublin, D. Montefiori, 2020, PLoS medicine.

Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost

P. Earl, B. Moss, N. Sardesai, 2017, The Journal of infectious diseases.

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

J. Kublin, D. Montefiori, H. Schuitemaker, 2020, The lancet. HIV.

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design

S. McCormack, M. Hoelscher, M. Robb, 2018, PloS one.

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

F. Piedimonte, W. Boersma, M. Bonten, 2021, The Lancet Infectious Diseases.

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime

S. McCormack, M. Hoelscher, M. Robb, 2012, Retrovirology.

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein

Allan C. deCamp, J. Kublin, S. Omarjee, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study

J. Kublin, D. Montefiori, H. Schuitemaker, 2022, The Journal of infectious diseases.

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial

S. McCormack, M. Hoelscher, M. Robb, 2016, PloS one.

Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial

B. Moss, S. McCormack, M. Hoelscher, 2015, PloS one.

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

P. Kremsner, M. Fotin‐Mleczek, G. Leroux-Roels, 2020, medRxiv.

Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity

S. Lazzaro, L. Oostvogels, Sarah-Katharina Kays, 2024, Vaccines.